ACTRN12606000535572终止2 期
A Multicentre, Phase II, Open Label Study to Evaluate the Safety of CUV1647 and to Evaluate the Effect of Subcutaneous Implants of CUV1647 on the Time to Artificially Provoked Symptoms in Patients with Erythropoietic Protoporphyria (EPP)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •Patients with EPP (confirmed by elevated free protoporphyrin in peripheral erythrocytes and/or ferrochelatase mutation)- Fitzpatrick skin types I to IV.
排除标准
- •Any other photodermatosis such as polymorphic light eruption (PLE), discoid lupus erythematosus (DLE) or solar urticaria- females who are pregnant, lactating or of child bearing age not using adequate methods of contraception- Any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations.- Acute history of drug or alcohol abuse (in the last 12 months).- History of disorders of the gastrointestinal, hepatic, renal, cardiovascular, respiratory, endocrine, neurological, haematological or systemic disease judged to be clinically significant by the Investigator.
研究者
相似试验
已完成
2 期
IPINIVO - A Pharmacodynamics study of Nivolumab in Combination with Ipilimumab in Patients with Advanced or Metastatic Solid Tumours'Advanced or Metastatic Solid TumoursCancer - Malignant melanomaCancer - Lung - Non small cellCancer - Hodgkin'sCancer - KidneyCancer - Head and neckCancer - BladderCancer - ProstateCancer - Bowel - Back passage (rectum) or large bowel (colon)Cancer - BrainCancer - Other cancer typesACTRN12617001059358Clinical Network Services21
进行中（未招募）
1 期
Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell LymphomaTreatment Naïve Mantle Cell LymphomaCTIS2023-505205-16-00AstraZeneca AB100
进行中（未招募）
1 期
A study to investigate anti-tumor activity and safety of trastuzumab deruxtecan in patients with solid tumors carrying specific HER2 mutations.Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology.EUCTR2020-002368-30-FRAstraZeneca AB100
招募中
2 期
A clinical trial to evaluate the efficacy and safety of Trastuzumab Deruxtecan in treating patients with HER2 positive Solid TumorsCTRI/2021/03/031930AstraZeneca AB
进行中（未招募）
1 期
A study to investigate anti-tumor activity and safety of trastuzumab deruxtecan in patients with solid tumors carrying specific HER2 mutations.Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology.MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-002368-30-DKAstraZeneca AB100